 |
pyridopyrimidinone SMN2 splicing modifier |
|---|---|
| Trade Name | |
| Orphan Indication | Spinal muscular atrophy |
| USA Market Approval | USA |
| USA Designation Date | 2017-01-04 00:00:00 |
| Sponsor | Hoffmann-La Roche, Inc.;c/o Genentech, Inc., 1 DNA Way;South San Francisco, California, 94080 |
Related Access Program
Pfizer – Non Small Cell Lung Cancer With ALK or ROS1 Rearrangement
Pfizer – Non Small Cell Lung Cancer Harboring Molecular Alterations
Biogen – Infantile-onset Spinal Muscular Atrophy
Novartis Pharmaceuticals – Non-small Cell Lung Cancer (NSCLC)
Biogen – Infantile-onset Spinal Muscular Atrophy (SMA)